Search Result

Results for "

nonalcoholic steatohepatitis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (20) Acetyl-CoA Carboxylase (4) ACSL Family (1) Acyltransferase (4) Amino acid Transporter (1) Aminotransferases (Transaminases) (1) AMPK (2) Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (6) ASK1 (2) Autophagy (5) Bacterial (1) Biochemical Assay Reagents (2) Carboxypeptidase (2) Caspase (1) CCR (2) ClpP (1) Cyclophilin (1) Cytochrome P450 (4) Dipeptidyl Peptidase (1) Drug Derivative (1) Drug Isomer (1) Drug Metabolite (2) Endogenous Metabolite (6) Epoxide Hydrolase (1) ERK (1) Eukaryotic Initiation Factor (eIF) (1) FAP (1) Ferroptosis (1) FGFR (1) Free Fatty Acid Receptor (2) FXR (15) G protein-coupled Bile Acid Receptor 1 (1) GCGR (9) GLP Receptor (16) GLUT (1) Glutathione Peroxidase (1) Glutathione S-transferase (1) GPR119 (2) HCV (2) HIV (1) HMG-CoA Reductase (HMGCR) (1) HSP (1) Insulin Receptor (1) Interleukin Related (4) IRE1 (1) Isotope-Labeled Compounds (4) JNK (1) Keap1-Nrf2 (3) Ketohexokinase (2) LDLR (2) Lipoxygenase (1) Lysyl Oxidase (1) MAP3K (1) Mineralocorticoid Receptor (2) Mitochondrial Metabolism (5) Neurokinin Receptor (1) NF-κB (4) NOD-like Receptor (NLR) (4) Nuclear Factor of activated T Cells (NFAT) (1) OAT (1) p38 MAPK (1) PARP (1) PCSK9 (1) Phosphatase (1) PPAR (9) Quinone Reductase (1) RAR/RXR (2) Reactive Oxygen Species (ROS) (5) Reference Standards (7) Sirtuin (1) SphK (2) STAT (2) Stearoyl-CoA Desaturase (SCD) (1) TAM Receptor (1) TGF-beta/Smad (2) Thyroid Hormone Receptor (9) TNF Receptor (5) Toll-like Receptor (TLR) (1) Tyrosinase (1)
By Research Areas:	Cancer (18) Cardiovascular Disease (14) Endocrinology (2) Infection (3) Inflammation/Immunology (74) Metabolic Disease (90) Neurological Disease (9)
Oligonucleotides:	Phospholipids (1)

138

Inhibitors & Agonists

Bibliotecas de Screening

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-12216

Resmetirom Maximum Cited Publications 22 Publications Verification MGL-3196; VIA-3196	Thyroid Hormone Receptor	Cardiovascular Disease Endocrinology
Resmetirom (MGL-3196) is a highly selective and orally active thyroid hormone receptor β (THR-β) agonist with an EC₅₀ value of 0.21 μM. Resmetirom can be used for the study of noncirrhotic nonalcoholic steatohepatitis .

HY-P99930

Efruxifermin 2 Publications Verification AKR-001; AMG-876	FGFR	Metabolic Disease
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .

HY-116374

Glycolithocholic acid 2 Publications Verification Lithocholylglycine	Endogenous Metabolite	Inflammation/Immunology
Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-109083

Cilofexor 5+ Cited Publications GS-9674	FXR Autophagy	Inflammation/Immunology
Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC₅₀ of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research .

HY-P3463

Beinaglutide 1 Publications Verification GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-19796

Icomidocholic acid 1 Publications Verification Aramchol; C20-FABAC	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
Icomidocholic acid (Aramchol) is a lipid molecule synthesized from cholic acid and arachidic acid. Icomidocholic acid is an orally active SCD1 inhibitor and cholesterol solubilizer with antifibrotic effects. Icomidocholic acid can reduce liver fat content, dissolve cholesterol crystals and prevent gallstone formation. Icomidocholic acid can be used in the study of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .

HY-145632

Pemvidutide ALT-801	GLP Receptor GCGR	Metabolic Disease
Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research .

HY-147246

Berberine ursodeoxycholate 1 Publications Verification HTD1801; BUDCA	Biochemical Assay Reagents	Metabolic Disease
Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes .

HY-148814

BI-3231 2 Publications Verification	17β-HSD	Metabolic Disease
BI 3231, a chemical probe, is a potent and selective hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) inhibitor, with IC₅₀s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases .

HY-164774

(4S)-GLP-1 receptor agonist 14	GLP Receptor	Metabolic Disease Inflammation/Immunology
(4S)-GLP-1 receptor agonist 14 is a potent and orally active GLP-1 receptor agonist with an EC₅₀ ≤ 20 nM. (4S)-GLP-1 receptor agonist 14 can be used for research on diabetes, obesity, metabolic diseases, cardiovascular diseases, liver diseases, nonalcoholic steatohepatitis (NASH), and other diseases associated with GLP-1 receptor .

HY-119039

RU-301 1 Publications Verification	TAM Receptor	Inflammation/Immunology Cancer
RU-301 is a pan TAM inhibitor that blocks Gas6-induced TAM activation and tumorigenicity. RU-301 significantly reduces nonalcoholic steatohepatitis (NASH) fibrosis, along with attenuates ERK activation and TGFβ1 expression. RU-301 can be used in studies of cancer and nonalcoholic steatohepatitis .

HY-108022

Azemiglitazone 1 Publications Verification MSDC-0602	Mitochondrial Metabolism PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
Azemiglitazone (MSDC-0602) is an orally active thiazolidinedione (TZD) -like molecule, which binds to PPARγ with low binding and activating affinity. Azemiglitazone inhibits mitochondrial pyruvate carrier (MPC), which inhibits Alzheimer’s disease and diminishes nonalcoholic steatohepatitis (NASH) caused liver injury .

HY-P99697

Leronlimab PRO 140	CCR HIV	Infection Cancer
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .

HY-160004

PXL770	AMPK	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
PXL770 is an orally active, direct allosteric AMP-activated protein kinase (AMPK) activator. PXL770 decreases C26:0 levels, improves mitochondrial respiration, reduces expression of proinflammatory genes and induces expression of compensatory transporters (ABCD2/3) in ALD fibroblasts/lymphocytes. PXL770 normalizes plasma VLCFA levels, significantly reduces elevated VLCFA levels in brain and spinal cord in Abcd1 KO mice. PXL770 improves glycemia, dyslipidemia, and insulin resistance in ob/ob and high-fat diet (HFD)-fed mice. PXL770 can be used for the study of X-linked adrenoleukodystrophy (ALD), autosomal dominant polycystic kidney disease and nonalcoholic steatohepatitis (NASH) .

HY-101190

Volixibat SHP626; LUM002	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH) .

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease Inflammation/Immunology
GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC₅₀ of 0.57 nM for GLP-1R and an EC₅₀ of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .

HY-143613

THR-β agonist 2	Thyroid Hormone Receptor	Metabolic Disease
THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .

HY-135644

Rencofilstat 1 Publications Verification CRV431	Cyclophilin Sirtuin Nuclear Factor of activated T Cells (NFAT) Interleukin Related	Cancer
Rencofilstat (CRV431) is an orally active pan-cyclophilin inhibitor with IC₅₀ values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease. Rencofilstat can be used for the study of nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and viral hepatitis-induced liver disease .

HY-109096

Nidufexor LMB763	FXR Autophagy	Inflammation/Immunology
Nidufexor (LMB763) is an orally-available farnesoid X receptor (FXR) agonist for the research of nonalcoholic steatohepatitis (NASH) .

HY-147296

Omesdafexor MET409	FXR	Inflammation/Immunology Cancer
Omesdafexor (MET409) is an orally active FXR agonist with a unique non-bile acid structure. Omesdafexor can be used for the study of non-alcoholic steatohepatitis (NASH) .

HY-W044764

2-Benzylsuccinic acid 1 Publications Verification DL-Benzylsuccinic acid	Carboxypeptidase	Neurological Disease Metabolic Disease
2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis .

HY-134988

EDP-305	FXR Phosphatase Cytochrome P450	Inflammation/Immunology
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .

HY-149987

LY3522348 KHK-IN-3	Ketohexokinase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
KHK-IN-3 (Example 1) is a ketohexokinase (KHK) inhibitor. KHK-IN-3 can be used in the study of kidney disease, nonalcoholic steatohepatitis (NASH), diabetes and heart failure. KHK is a rate-limiting enzyme and fructokinase involved in fructose metabolism. KHK catalyzes the phosphorylation of fructose to fructose-1-phosphate (FIP) at the expense of ATP. The lack of feedback inhibition of fructose metabolism triggers the accumulation of downstream intermediates such as lipogenesis, gluconeogenesis, and oxidative phosphorylation .

HY-116374A

Glycolithocholic acid sodium 2 Publications Verification Lithocholylglycine sodium	Endogenous Metabolite	Metabolic Disease
Glycolithocholic acid (Lithocholylglycine) sodium is the sodium salt of Glycolithocholic acid. Glycolithocholic acid is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-153476A

GIP/GLP-1 dual receptor agonist-1 sodium	GLP Receptor GCGR	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-153476

GIP/GLP-1 dual receptor agonist-1	GCGR GLP Receptor	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-103479

GOAT-IN-1	Acyltransferase	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.

HY-113111

11,12-DiHETrE	Drug Metabolite	Inflammation/Immunology
11,12-DiHETrE is a dihydroxy fatty acid metabolite of Arachidonic Acid (HY-109590). 11,12-DiHETrE is converted to 11,12-DiHETrE under elevated soluble epoxide hydrolase (sEH) activity, a process closely related to inflammation and oxidative stress. 11,12-DiHETrE can serve as a single biomarker to differentiate between NAFL (non-alcoholic fatty liver disease) and NASH (non-alcoholic steatohepatitis). 11,12-DiHETrE can be used in studies on preterm birth, autism, and pulmonary hypertension .

HY-147055

THR-β agonist 5	Thyroid Hormone Receptor	Metabolic Disease Inflammation/Immunology
THR-β agonist 5 is a THR-β agonist. THR-β agonist 5 can be used for the research of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis .

HY-121212

Icosabutate	Free Fatty Acid Receptor PPAR Apoptosis	Inflammation/Immunology
Icosabutate is an orally active engineered fatty acid and a dual FFAR1/FFAR4 (GPR40/GPR120) agonist with EC₅₀ values of 10 μM and 15.5 μM, respectively. Icosabutate acts as a partial agonist of PPAR-α, with an EC₅₀ of 208 nM. Icosabutate inhibits the arachidonic acid cascade and exhibits antioxidant and anti-apoptotic activities. Icosabutate can be used in the research of nonalcoholic steatohepatitis, metabolic dysfunction-associated steatohepatitis, and atherosclerosis .

HY-W996116

AZM198	Glutathione Peroxidase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
AZM198 is an orally active myeloperoxidase (MPO) inhibitor. AZM198 irreversibly inactivates MPO (IC₅₀=0.015 μM) via covalent binding to the heme prosthetic group, preferentially targets extracellular MPO activity, and reduces neutrophil extracellular trap formation, reactive oxygen species production and degranulation. AZM198 increases the fibrous cap thickness of atherosclerotic plaques, reduces lesion area, ameliorates hepatic steatosis and fibrosis in non-alcoholic steatohepatitis, and alleviates proteinuria and inflammatory infiltration associated with glomerulonephritis. AZM198 also decreases circulating levels of high-sensitivity Cardiac Troponin I and IL-1β, and mitigates endothelial cell injury. Therefore, AZM198 is suitable for research on various MPO-related diseases, including atherosclerotic cardiovascular disease, myocardial infarction, ischemic stroke, non-alcoholic steatohepatitis and crescentic glomerulonephritis .

HY-156065

S217879	Keap1-Nrf2 Reactive Oxygen Species (ROS) Interleukin Related	Metabolic Disease
S217879 is an orally active and selective NRF2 activator. S217879 activates the NRF2 pathway by specifically disrupting the KEAP1 (K_d: 4.15 nM)-NRF2 interaction, and upregulates the antioxidant response. S217879 also ameliorates steatohepatitis and reduces the degree of liver fibrosis. S217879 can be used in the research of metabolic dysfunction-associated steatotic liver disease and nonalcoholic steatohepatitis .

HY-145632A

Pemvidutide TFA ALT-801 TFA	GLP Receptor GCGR	Metabolic Disease
Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research .

HY-146997

TRβ agonist 1	Thyroid Hormone Receptor	Metabolic Disease
TRβ agonist 1 is a selective and mutation-sensitive thyroid hormone receptor β (TRβ) agonist, with an EC₅₀ value of 21 nM. TRβ agonist 1 can be used for researching dyslipidemia, nonalcoholic steatohepatitis (NASH), and resistance to thyroid hormone (RTH) .

HY-169792

HPG1860	FXR Aminotransferases (Transaminases)	Metabolic Disease Inflammation/Immunology
HPG1860 is an orally active, highly selective and potent FXR agonist, with an EC₅₀ of 18 nM (FXR-luciferase reporter assay). HPG1860 has EC₅₀ values >30.0 μM for TGR5 and 13 other related nuclear receptors (cAMP biological assay). HPG1860 can be used for the research of non-alcoholic steatohepatitis (NASH) .

HY-144111

PPARα/δ agonist 1	PPAR	Inflammation/Immunology
PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist (PPARα EC₅₀=7.0 nM; PPARδ EC₅₀=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC₅₀=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .

HY-19522C

Seladelpar (lysine dihydrate) 1 Publications Verification MBX-8025 (lysine dihydrate); RWJ-800025 (lysine dihydrate)	PPAR Interleukin Related	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Seladelpar Lysine dihydrate (MBX-8025 lysine dihydrate) is an orally active, selective PPAR-δ agonist with an EC₅₀ of 2 nM against hPPAR-δ. Seladelpar Lysine dihydrate reduces serum IL-31 and bile acid levels. It alleviates pruritus symptoms. Seladelpar Lysine dihydrate enhances insulin sensitivity, normalizes levels of hyperglycemia, hyperinsulinemia, glucose disposal capacity, serum lipids and hepatic free cholesterol. It reduces steatosis, hepatic inflammation and improves liver fibrosis. Seladelpar Lysine dihydrate reverses the pathological changes of non-alcoholic steatohepatitis (NASH). It is applicable to research related to primary biliary cholangitis and non-alcoholic steatohepatitis (NASH) .

HY-144035

GLP-1R agonist 4	GCGR	Metabolic Disease Inflammation/Immunology
GLP-1R agonist 4 is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 can be used for the research of type 2 diabetes mellitus, obesity, non-alcoholic steatohepatitis, insulin resistance and etc .

HY-163071

V023-9340	FXR	Metabolic Disease
V023-9340 is a potent FXR inhibitor with IC₅₀ of 4.27 μM that can be used in NASH (nonalcoholic steatohepatitis) research .

HY-109002

Apararenone MT-3995	Mineralocorticoid Receptor	Cardiovascular Disease Metabolic Disease
Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.

HY-116374S

Glycolithocholic acid-d4	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
Glycolithocholic acid-d₄ is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-149831

ZLY28	FXR	Metabolic Disease
ZLY28 is the first-in-class intestinal restricted and orally active FXR and FABP1 dual modulator. ZLY28 also is a novel anti-NASH agent. ZLY28 can be used for the research of nonalcoholic steatohepatitis (NASH) .

HY-127108

ND-654	Acetyl-CoA Carboxylase	Metabolic Disease Cancer
ND-654 is a highly selective acetyl-CoA carboxylase (ACC) inhibitor (IC₅₀: ACC1=3 nM, ACC2=8 nM). ND-654 reduces hepatic lipogenesis, decreases neutrophil recruitment and promotes anti-inflammatory M2 macrophage polarization. ND-654 is promising for research of nonalcoholic steatohepatitis and hepatocellular carcinoma .

HY-150191

IMA-1	Lipoxygenase Acetyl-CoA Carboxylase	Metabolic Disease
IMA-1 is an inhibitor that inhibits the interaction between arachidonic acid 12-lipoxygenase (ALOX12) and acetyl-CoA carboxylase 1 (ACC1). IMA-1 significantly blocks the progression of diet-induced non-alcoholic steatohepatitis (NASH) in male mice and crab-eating monkeys, and does not cause hyperlipidemia. IMA-1 can be used for the study of NASH .

HY-116374R

Glycolithocholic acid (Standard) Lithocholylglycine (Standard)	Endogenous Metabolite Reference Standards	Inflammation/Immunology
Glycolithocholic acid (Standard) is the analytical standard of Glycolithocholic acid. This product is intended for research and analytical applications. Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-159595

PCSK9-IN-29	LDLR PCSK9	Metabolic Disease Inflammation/Immunology
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .

HY-176873

SLC6A19-IN-2	Amino acid Transporter	Metabolic Disease
SLC6A19-IN-2 (Example 4) is a potent SLC6A19 inhibitor with an IC₅₀ of 14 nM. SLC6A19-IN-2 can be used for the study of metabolic diseases such as nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD) and phenylketonuria (PKU) .

HY-N10640

Alismanol M	FXR	Inflammation/Immunology
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis .

HY-156034A

JT001 sodium NLRP3-IN-19 sodium	NOD-like Receptor (NLR)	Inflammation/Immunology
JT001 (NLRP3-IN-19) sodium is a potent, specific and orally active inhibitor of NLRP3. JT001 sodium can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 sodium can be used for the research of nonalcoholic steatohepatitis and liver fibrosis .

HY-156034

JT001 NLRP3-IN-19	NOD-like Receptor (NLR)	Inflammation/Immunology
JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis .

Cat. No.	Nombre del producto

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

4,779 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 4,779 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Cat. No.	Nombre del producto	Type

HY-N7864

Osbond acid

all-cis-4,7,10,13,16-Docosapentaenoic acid

Biochemical Assay Reagents

Docosapentaenoic acid (DPA) is a 22-carbon fatty acid found in fish oil. It is a minor component of total serum unsaturated fatty acids in humans, ranging from 0.1% to 1%, and increasing with dietary supplementation. all-cis-4,7,10,13,16-DPA, also known as Austrian acid, is an isomer of DPA. It is an omega-6 fatty acid formed by the extension and desaturation of arachidonic acid. During fatty acid desaturase syndrome, levels of this fatty acid may be reduced, which may affect development. Upregulated hepatic elongate expression of very long fatty acid protein 6 and elevated levels of very long chain fatty acids, including all-cis 4,7,10,13,16-DPA, are characteristic of nonalcoholic steatohepatitis, a precancerous disease of hepatocellular carcinoma.

Cat. No.	Nombre del producto	Target	Research Area

HY-P3463

Beinaglutide 1 Publications Verification GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-145632

Pemvidutide ALT-801	GLP Receptor GCGR	Metabolic Disease
Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research .

HY-P10302A

GLP-1R/GIPR agonist-1 (soduim)	GLP Receptor	Metabolic Disease Inflammation/Immunology
GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC₅₀ of 0.57 nM for GLP-1R and an EC₅₀ of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .

HY-153476A

GIP/GLP-1 dual receptor agonist-1 sodium	GLP Receptor GCGR	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-153476

GIP/GLP-1 dual receptor agonist-1	GCGR GLP Receptor	Inflammation/Immunology
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .

HY-145632A

Pemvidutide TFA ALT-801 TFA	GLP Receptor GCGR	Metabolic Disease
Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P11042

TE-8105	GLP Receptor	Metabolic Disease
TE-8105 is a GLP-1 receptor agonist that has demonstrated prolonged and potent efficacy in models of diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P10337

OXM-7	GCGR GLP Receptor	Metabolic Disease Endocrinology
OXM-7 is a dual agonist of GLP-1R (EC₅₀=0.024 nM) and GCGR (EC₅₀=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .

HY-P6177

SGP8	Dipeptidyl Peptidase	Inflammation/Immunology
SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH) .

Cat. No.	Nombre del producto	Target	Research Area	Image

HY-P99930

Efruxifermin 2 Publications Verification AKR-001; AMG-876	FGFR	Metabolic Disease
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .

HY-P991049

Atrosimab ATM-001	TNF Receptor	Metabolic Disease Inflammation/Immunology
Atrosimab is an Fv-Fc1K fusion protein with an EC₅₀ value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis .

HY-P99428

Aldafermin NGM282	Inhibitory Antibodies	Metabolic Disease
Aldafermin (NGM282) is an analog of fibroblast growth factor 19. Aldafermin can be used for the research of nonalcoholic steatohepatitis (NASH) .

HY-P99697

Leronlimab PRO 140	CCR HIV	Infection Cancer
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .

HY-P99143

Anti-Mouse NK1.1 Antibody (PK136)	Neurokinin Receptor NF-κB STAT	Inflammation/Immunology
Anti-Mouse NK1.1 Antibody (PK136) is an anti-mouse NK1.1 IgG2a monoclonal antibody. Anti-Mouse NK1.1 Antibody (PK136) can deplete natural killer (NK) cells. Anti-Mouse NK1.1 Antibody (PK136) inhibits the JAK-STAT and NF-κB signaling pathways. Anti-Mouse NK1.1 Antibody (PK136) can be used for research on inflammation conditions such as non-alcoholic steatohepatitis (NASH) .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-116374

Glycolithocholic acid 2 Publications Verification Lithocholylglycine	Human Gut Microbiota Metabolites Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Steroids Source Classification	Endogenous Metabolite
Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-W011121

2-Oleoylglycerol 1 Publications Verification 2-OG	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Lipid Source Classification	GPR119 NF-κB TGF-beta/Smad GLP Receptor
2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC₅₀ value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .

HY-N1775

3',4'-Dihydroxyacetophenone 3,4-DHAP	Structural Classification Classification of Application Fields Pinaceae Phenols Polyphenols Picea schrenkiana Fisch. et Mey. Plants Disease Research Fields Source Classification Cancer	Tyrosinase Reactive Oxygen Species (ROS) Keap1-Nrf2 PARP Autophagy Apoptosis
3',4'-Dihydroxyacetophenone (3,4-DHAP) is a phenolic compound with oral bioavailability, possessing potent antioxidant, anti-inflammatory, anticancer and cardiovascular protective activities. 3',4'-Dihydroxyacetophenone inhibits mushroom Tyrosinase activity with an IC₅₀ of 10 μM, thereby suppressing melanogenesis . 3',4'-Dihydroxyacetophenone inhibits platelet aggregation in platelet-rich plasma. 3',4'-Dihydroxyacetophenone reduces ROS levels in human umbilical vein endothelial cells treated with high glucose, upregulates the expression of Nrf2, HO-1 and PARP-1 in cells, and promotes the nuclear translocation of Nrf2 . 3',4'-Dihydroxyacetophenone induces autophagy and apoptosis. 3',4'-Dihydroxyacetophenone inhibits seed germination/growth in most plants. 3',4'-Dihydroxyacetophenone can be used in the research of cancer, neurodegenerative diseases, non-alcoholic steatohepatitis, diabetes, obesity, skin pigmentation disorders, and cardiovascular and cerebrovascular diseases .

HY-116374R

Glycolithocholic acid (Standard) Lithocholylglycine (Standard)	Structural Classification Human Gut Microbiota Metabolites Endogenous metabolite Steroids Source Classification	Endogenous Metabolite Reference Standards
Glycolithocholic acid (Standard) is the analytical standard of Glycolithocholic acid. This product is intended for research and analytical applications. Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-N16066

Candidusin A CHNQD-0803	Monophenols Microorganisms Phenols Source Classification	AMPK Apoptosis NF-κB TNF Receptor
Candidusin A (CHNQD-0803) (Compound 4) is a AMPK activator with a K_D of 47.28 nM. Candidusin A can be isolated from marine fungus Aspergillus candidus. Candidusin A has cytotoxic activity and induces apoptosis in human prostate cancer cells (22Rv1, PC-3 and LNCaP cells). Candidusin A reduces adipogenesis genes expression and fat deposition, negatively regulates the NF-κB-TNFα inflammatory axis to suppress inflammation, and ameliorates liver injury and fibrosis. Candidusin A can be used for non-alcoholic steatohepatitis (NASH) research .

HY-N10640

Alismanol M	Triterpenes Terpenoids Alisma orinentale (Samuel.) Juz. Plants Alismataceae	FXR
Alismanol M is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis .

HY-N19083

Tecomella undulata extract	Structural Classification Extract	Bacterial
Tecomella undulata Extract, also known as Rohida extract, is a valuable botanical extract derived from the bark and leaves of the Tecomella undulata plant native to the Indian Thar Desert and is rich in bioactive compounds such as flavonoids, quinones, triterpenoids, and other phytochemicals that contribute to its diverse therapeutic properties. This extract is widely recognized for its hepatoprotective effects demonstrated through its ability to protect against liver damage induced by toxins such as paracetamol and carbon tetrachloride by normalizing elevated liver enzyme levels reducing oxidative stress and improving liver function. Additionally, it exhibits significant anti-inflammatory activity comparable to standard drugs like indomethacin and has been used to treat conditions like ascites and hepatosplenomegaly while also showing immunomodulatory effects by enhancing both humoral and cell-mediated immune responses and possessing antimicrobial properties that make it effective against various pathogens. Recent research suggests that Tecomella undulata may have potential in managing nonalcoholic steatohepatitis (NASH) by reducing body weight insulin resistance and improving liver function markers making it a versatile natural remedy with significant applications in hepatoprotection anti-inflammation and immune support.

Cat. No.	Nombre del producto	Chemical Structure

HY-116374S

Glycolithocholic acid-d4
Glycolithocholic acid-d₄ is the deuterium labeled Glycolithocholic acid. Glycolithocholic acid, an endogenous metabolite, is a glycine-conjugated secondary bile acid and can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-W750488

Glycolithocholic acid-d5
Glycolithocholic acid-d₅ (Lithocholylglycine-d₅) is the deuterium labeled Glycolithocholic acid (HY-116374). Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) .

HY-W701772

2-Oleoylglycerol-d5

2-Oleoylglycerol-d₅ (2-OG-d₅) is the deuterium labeled 2-Oleoylglycerol (HY-W011121). 2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC₅₀ value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .

HY-181896S

PPARγ agonist-23
PPARγ agonist-23 (Compound 9) is an orally active PPARγ agonist with an EC₅₀ of 0.32 μM. PPARγ agonist-23 improves hepatic triglyceride levels, reduces scores of steatosis and hepatocellular ballooning, and decreases the total activity score of non-alcoholic steatohepatitis (NASH). PPARγ agonist-23 can be used for the research of non-alcoholic steatohepatitis .

HY-12216S

Resmetirom-13C3,15N
Resmetirom- ¹³C₃, ¹⁵N (MGL-3196- ¹³C₃, ¹⁵N) is the ¹³C- and ¹⁵N-labeled Resmetirom (HY-12216). Resmetirom (MGL-3196) is a highly selective and orally active thyroid hormone receptor β (THR-β) agonist with an EC₅₀ value of 0.21 μM. Resmetirom can be used for the study of noncirrhotic nonalcoholic steatohepatitis .

Cat. No.	Nombre del producto		Classification

HY-W140439

1-Oleoyl-sn-glycero-3-phosphocholine 18:1 Lyso PC		Phospholipids
1-Oleoyl-sn-glycero-3-phosphocholine (18:1 Lyso PC), a lysophospholipid, is a GPR82 inhibitor. 1-Oleoyl-sn-glycero-3-phosphocholine abrogates constitutive Gi-coupled GPR82 activity, shifts active/inactive equilibrium to inactive, suppresses Gi protein activation, increases cAMP production, and decreases GTPγS binding to Gαi proteins. 1-Oleoyl-sn-glycero-3-phosphocholine contributes to adipocyte lipolysis regulation.1-Oleoyl-sn-glycero-3-phosphocholine exhibits reduced serum levels in mouse models of steatohepatitis, linked to hepatic Lpcat 1-4 up-regulation .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

nonalcoholic steatohepatitis

Inhibitors & Agonists

Bibliotecas de Screening

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products